Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | KIT | P10721 | 8/20 | 0.48 |
| ▸ | FLT1 | P17948 | 7/20 | 0.48 |
| ▸ | FLT3 | P36888 | 7/20 | 0.48 |
| ▸ | CSF1R | P07333 | 6/20 | 0.48 |
| ▸ | LCK | P06239 | 5/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.48 |
| ▸ | LYN | P07948 | 4/20 | 0.48 |
| ▸ | BLK | P51451 | 4/20 | 0.48 |
| ▸ | GSK3B | P49841 | 4/20 | 0.48 |
| ▸ | FGFR3 | P22607 | 3/20 | 0.48 |
| ▸ | ABL1 | P00519 | 3/20 | 0.48 |
| ▸ | FYN | P06241 | 3/20 | 0.48 |
| ▸ | PLK4 | O00444 | 3/20 | 0.48 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.48 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4831096 | 0.90 | TP53 (0.48) | CA12CA1CA2CA9FLT1 | |
| SCHEMBL4833807 | 0.86 | RET (0.43) | LCKJAK2RETBTKKDR | |
| SCHEMBL4825658 | 0.86 | KDR (0.50) | KITFLT1FLT3CSF1RLCK | |
| SCHEMBL4833733 | 0.85 | MEN1 (0.36) | CA12CA1CA2CA9KIT | |
| SCHEMBL4828956 | 0.84 | CSF1R (0.41) | CA1CA2CSF1RLCKKDR | |
| SCHEMBL4831336 | 0.82 | KDR (0.50) | CA12CA1CA2CA9KIT | |
| SCHEMBL4825798 | 0.79 | CA12 (0.47) | CA12CA1CA2CA9KIT | |
| SCHEMBL4836418 | 0.79 | CSF1R (0.39) | CA1CA2CSF1RABL1NTRK1 | |
| SCHEMBL4836046 | 0.78 | PSEN1 (0.44) | NTRK1ROCK2RIPK1 | |
| SCHEMBL4831055 | 0.78 | DDX3X (0.47) | KITLCKBLKGSK3BPLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | claimed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | CA12 4081/4885CA1 4775/4885CA2 2721/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | CA12 4813/4885CA1 4873/4885CA2 3685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.